Repligen (NASDAQ:RGEN) Coverage Initiated by Analysts at Evercore ISI

Evercore ISI started coverage on shares of Repligen (NASDAQ:RGEN) in a research report report published on Tuesday morning, MarketBeat Ratings reports. The brokerage issued an in-line rating and a $155.00 target price on the biotechnology company’s stock.

Several other equities analysts have also issued reports on RGEN. Canaccord Genuity Group boosted their price target on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a report on Friday, February 21st. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. JPMorgan Chase & Co. upped their target price on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $178.64.

Repligen Price Performance

Shares of RGEN stock opened at $144.34 on Tuesday. Repligen has a 12-month low of $113.50 and a 12-month high of $200.23. The firm has a market capitalization of $8.09 billion, a price-to-earnings ratio of -283.02, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm has a fifty day moving average of $156.98 and a 200-day moving average of $148.49.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. On average, equities research analysts forecast that Repligen will post 1.72 earnings per share for the current year.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax purchased 250 shares of the business’s stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. This represents a 31.53 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Champlain Investment Partners LLC raised its holdings in shares of Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after purchasing an additional 850,345 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Repligen by 11.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after purchasing an additional 743,815 shares during the period. Point72 Asset Management L.P. raised its holdings in shares of Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock valued at $132,227,000 after purchasing an additional 594,189 shares during the period. Groupama Asset Managment raised its holdings in shares of Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock valued at $58,142,000 after purchasing an additional 400,680 shares during the period. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Repligen in the 4th quarter valued at about $53,428,000. 97.64% of the stock is owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.